Insmed Incorporated (NASDAQ:INSM) Insider Martina M.D. Flammer Sells 6,172 Shares

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 6,172 shares of the company’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $63.64, for a total value of $392,786.08. Following the completion of the transaction, the insider now owns 101,549 shares of the company’s stock, valued at approximately $6,462,578.36. This represents a 5.73 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Martina M.D. Flammer also recently made the following trade(s):

• On Tuesday, January 7th, Martina M.D. Flammer sold 3,344 shares of Insmed stock. The stock was sold at an average price of $65.91, for a total transaction of $220,403.04.

Insmed Trading Down 0.7 %

NASDAQ INSM opened at $65.25 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a one year low of $21.92 and a one year high of $80.53. The company has a 50-day simple moving average of $71.23 and a 200-day simple moving average of $72.44. The firm has a market capitalization of $11.67 billion, a PE ratio of -11.76 and a beta of 1.12.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The business had revenue of $93.40 million during the quarter, compared to the consensus estimate of $93.36 million. The firm’s revenue for the quarter was up 18.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.10) EPS. On average, equities analysts forecast that Insmed Incorporated will post -5.44 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Bank of America lifted their price target on shares of Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. JPMorgan Chase & Co. increased their price target on Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a report on Friday, November 22nd. HC Wainwright restated a “buy” rating and set a $90.00 price objective on shares of Insmed in a research note on Friday, November 1st. Finally, Truist Financial reiterated a “buy” rating and set a $105.00 target price (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Insmed has an average rating of “Moderate Buy” and a consensus target price of $83.67.

Institutional Investors Weigh In On Insmed

Several large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its position in shares of Insmed by 4.7% during the third quarter. Geode Capital Management LLC now owns 3,813,384 shares of the biopharmaceutical company’s stock worth $278,432,000 after acquiring an additional 172,664 shares during the last quarter. Darwin Global Management Ltd. bought a new position in Insmed in the 2nd quarter worth about $237,076,000. Principal Financial Group Inc. increased its stake in shares of Insmed by 12.9% in the third quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock valued at $136,648,000 after purchasing an additional 214,130 shares during the period. Clearbridge Investments LLC raised its holdings in shares of Insmed by 76.8% during the second quarter. Clearbridge Investments LLC now owns 1,644,948 shares of the biopharmaceutical company’s stock valued at $110,212,000 after buying an additional 714,539 shares during the last quarter. Finally, Vestal Point Capital LP raised its holdings in shares of Insmed by 113.3% during the third quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after buying an additional 850,000 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.